134 related articles for article (PubMed ID: 27681846)
1. How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.
Richman SD; Fairley J; Butler R; Deans ZC
J Clin Pathol; 2017 Jan; 70(1):58-62. PubMed ID: 27681846
[TBL] [Abstract][Full Text] [Related]
2. RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016).
Richman SD; Fairley J; Butler R; Deans ZC
Virchows Arch; 2017 Dec; 471(6):721-729. PubMed ID: 28653203
[TBL] [Abstract][Full Text] [Related]
3. Results of the UK NEQAS for Molecular Genetics reference sample analysis.
Richman SD; Fairley J; Hall JA; Nataraj N; Bhide M; Lau A; Norman KL; Deans ZC
J Clin Pathol; 2018 Nov; 71(11):989-994. PubMed ID: 30030291
[TBL] [Abstract][Full Text] [Related]
4. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.
Normanno N; Pinto C; Castiglione F; Fenizia F; Barberis M; Marchetti A; Fontanini G; De Rosa G; Taddei GL
J Transl Med; 2015 Sep; 13():287. PubMed ID: 26335936
[TBL] [Abstract][Full Text] [Related]
5. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
[TBL] [Abstract][Full Text] [Related]
6. RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.
Boleij A; Tack V; Taylor A; Kafatos G; Jenkins-Anderson S; Tembuyser L; Dequeker E; van Krieken JH
BMC Cancer; 2016 Oct; 16(1):825. PubMed ID: 27784278
[TBL] [Abstract][Full Text] [Related]
7. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
Allegra CJ; Rumble RB; Hamilton SR; Mangu PB; Roach N; Hantel A; Schilsky RL
J Clin Oncol; 2016 Jan; 34(2):179-85. PubMed ID: 26438111
[TBL] [Abstract][Full Text] [Related]
8. RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment.
Tack V; Ligtenberg MJL; Siebers AG; Rombout PDM; Dabir PD; Weren RDA; van Krieken JHJM; Dequeker EMC
Virchows Arch; 2018 May; 472(5):717-725. PubMed ID: 29333594
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
[TBL] [Abstract][Full Text] [Related]
10. Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing.
Harlé A; Filhine-Tresarrieu P; Husson M; Boidot R; Rouyer M; Dubois C; Leroux A; Merlin JL
Target Oncol; 2016 Jun; 11(3):363-70. PubMed ID: 26661077
[TBL] [Abstract][Full Text] [Related]
11. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.
Boleij A; Tops BB; Rombout PD; Dequeker EM; Ligtenberg MJ; van Krieken JH;
Oncotarget; 2015 Jun; 6(17):15681-9. PubMed ID: 25944693
[TBL] [Abstract][Full Text] [Related]
12. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.
Normanno N; Pinto C; Castiglione F; Bardelli A; Gambacorta M; Botti G; Nappi O; Siena S; Ciardiello F; Taddei G; Marchetti A
PLoS One; 2011; 6(12):e29146. PubMed ID: 22216189
[TBL] [Abstract][Full Text] [Related]
14. Use of a High-Throughput Genotyping Platform (OncoMap) for
Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
[TBL] [Abstract][Full Text] [Related]
15. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
Vaughn CP; Zobell SD; Furtado LV; Baker CL; Samowitz WS
Genes Chromosomes Cancer; 2011 May; 50(5):307-12. PubMed ID: 21305640
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.
Deans ZC; Tull J; Beighton G; Abbs S; Robinson DO; Butler R
Genet Test Mol Biomarkers; 2011 Nov; 15(11):777-83. PubMed ID: 21851273
[TBL] [Abstract][Full Text] [Related]
17. [Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].
Blons H; Laurent-Puig P
Bull Cancer; 2009 Dec; 96 Suppl():S47-56. PubMed ID: 20034870
[TBL] [Abstract][Full Text] [Related]
18. [KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].
Dubská L; Vyskocilová M; Nenutil R; Valík D; Knoflícková D; Fabian P; Kocáková I; Demlová R; Beránek M; Drastíková M; Vosmiková H; Bóday A; Horká K; Símová J; Drábek J; Ehrmann J; Hajdúch M; Matejcková M; Síma R; Tvrdík D; Povýsil C; Ryska A
Cas Lek Cesk; 2011; 150(6):321-6. PubMed ID: 21751504
[TBL] [Abstract][Full Text] [Related]
19. [Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment].
Bibeau F; Louvet C; Afchain P; Mitry E; Artru P; André T
Bull Cancer; 2012; 99(7-8):743-51. PubMed ID: 22735045
[TBL] [Abstract][Full Text] [Related]
20. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
